{"disease":{"id":"myelodysplastic-syndrome","name":"Myelodysplastic syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":11,"pipeline_drug_count":0,"trial_count":78},"drugs":{"marketed":[{"drug_id":"lenalidomide","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revlimid","generic_name":"lenalidomide","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)","drug_class":"Thalidomide analogue","quality_score":10,"revenue":"5809","mechanism":"Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation."},{"drug_id":"luspatercept","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reblozyl","generic_name":"LUSPATERCEPT","company_name":"Celgene Corp","drug_phase":"marketed","molecular_target":"Growth/differentiation factor 11","drug_class":"Erythroid Maturation Agent [EPC]","quality_score":60,"revenue":"2327","mechanism":"Reblozyl works by binding to growth/differentiation factor 11, promoting the maturation of red blood cells."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."},{"drug_id":"decitabine","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dacogen","generic_name":"decitabine","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Dacogen works by inhibiting the enzyme that adds methyl groups to DNA, which helps to restore normal gene function in cancer cells."},{"drug_id":"inqovi","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inqovi","generic_name":"Inqovi","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Cytidine deaminase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Inqovi works by blocking the enzyme cytidine deaminase, allowing chemotherapy medications to be more effective."},{"drug_id":"azacitidine","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"dacogen","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dacogen","company_name":"Mayo Clinic","drug_phase":"discontinued","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"azacytidine","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"azacytidine","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"luspatercept-aamt","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"REBLOZYL","generic_name":"LUSPATERCEPT-AAMT","company_name":"CELGENE CORP","drug_phase":"marketed","molecular_target":"Growth/differentiation factor 11, Growth/differentiation factor 8","drug_class":"Erythroid Maturation Agent [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of myelodysplastic syndromes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"lenali","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lenali","company_name":"Singapore General Hospital","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cedazuridine","indication_name":"Myelodysplastic Syndromes (MDS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEDAZURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"DNA methyltransferase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":45,"revenue":null,"mechanism":"Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation and cellular differentiation or apoptosis."},{"drug_id":"revlimid","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Revlimid","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"reblozyl","indication_name":"Myelodysplastic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Reblozyl","company_name":"EuroBloodNet Association","drug_phase":"marketed","molecular_target":"Growth/differentiation factor 11, Growth/differentiation factor 8","drug_class":"","quality_score":13,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04889729","title":"GENOMED4ALL: Improving MDS Classification and Prognosis by AI","phase":"","overall_status":"UNKNOWN","enrollment_count":13284,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT04676945","title":"Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients","phase":"","overall_status":"COMPLETED","enrollment_count":9179,"lead_sponsor_name":"Michael Pfeilstöcker","has_results":false},{"nct_id":"NCT04174547","title":"An European Platform for Translational Research in Myelodysplastic Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":8670,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT06956755","title":"Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia","phase":"","overall_status":"RECRUITING","enrollment_count":6990,"lead_sponsor_name":"Groupe Francophone des Myelodysplasies","has_results":false},{"nct_id":"NCT00900198","title":"Collection of Tissue Samples for Cancer Research","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02921802","title":"A Study of Special Use Results Surveillance of Revlimid 5mg Capsules","phase":"","overall_status":"COMPLETED","enrollment_count":4626,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT03169296","title":"Clinical and Genomic Registry of MDS in Asia","phase":"","overall_status":"UNKNOWN","enrollment_count":2600,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02775383","title":"The National Myelodysplastic Syndromes (MDS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":2115,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT01688011","title":"Connect® Myeloid Disease Registry","phase":"","overall_status":"TERMINATED","enrollment_count":2013,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02958462","title":"Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03904134","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1753,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT01602211","title":"INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT01595295","title":"Registry on Hypomethylating Agents in Myeloid Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT07102849","title":"Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1400,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07465029","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05350748","title":"Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05588154","title":"Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT04060485","title":"Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06681363","title":"Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04212390","title":"Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","has_results":false},{"nct_id":"NCT03839771","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":968,"lead_sponsor_name":"Stichting Hemato-Oncologie voor Volwassenen Nederland","has_results":false},{"nct_id":"NCT04726241","title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"PedAL BCU, LLC","has_results":false},{"nct_id":"NCT05444348","title":"Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)","phase":"NA","overall_status":"RECRUITING","enrollment_count":920,"lead_sponsor_name":"Christoffer Johansen","has_results":false},{"nct_id":"NCT06790680","title":"GITMO AML/MDS-Relapse Registry Study","phase":"","overall_status":"COMPLETED","enrollment_count":859,"lead_sponsor_name":"Gruppo Italiano Trapianto di Midollo Osseo","has_results":false},{"nct_id":"NCT03335943","title":"Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Chinese Society of Hematology","has_results":false},{"nct_id":"NCT02085408","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":727,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT01929408","title":"Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06487247","title":"HEME Home Transfusion Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":665,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04988555","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT00822393","title":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":570,"lead_sponsor_name":"medac GmbH","has_results":false},{"nct_id":"NCT00923442","title":"Biology Studies of Hematologic Cancers","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":550,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04313881","title":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":539,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04266301","title":"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":530,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02137629","title":"Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT07019155","title":"Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants","phase":"","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02085798","title":"Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)","phase":"","overall_status":"COMPLETED","enrollment_count":503,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT07355478","title":"Asia Myelodysplastic Syndrome (MDS) Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT00481273","title":"AVIDA The Vidaza® (Azacitidine) Patient Registry","phase":"","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT03268954","title":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT00074490","title":"Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":442,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05457556","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":435,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06971185","title":"A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01119066","title":"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":422,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT06851065","title":"A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02907359","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":417,"lead_sponsor_name":"Astex Pharmaceuticals, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}